United Therapeutics Corporation - Common Stock (NQ:UTHR)

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

1 Mid-Cap Stock to Research Further and 2 That Underwhelm

October 01, 2026

Performance

52-Week Range 10.1% below 52-week high

548.08

409.0752W Low 609.3552W High

1 Week 6.4% below 1-week high

470.401W Low 585.791W High

United Therapeutics Corporation - Common Stock (UTHR) traded between $409.07 and $609.35 over the past 52 weeks and last traded at $548.08, 10.1% below its 52-week high. Over the past week it ranged between $470.40 and $585.79.

Past 12 Months

+15.3%

+6.9%

-1.4%

-3.0%

+10.3%

+25.1%

1W +$72.63

1M +$35.38

3M -$7.83

6M -$16.73

YTD +$51.36

1Y +$109.90

UTHR was +25.1% over the past year, -3.0% over six months, +10.3% year to date, +15.3% in the last week.

12 Months vs Market

UTHR

+25.1%

DIA

+10.0%

SPY

+15.1%

QQQ

+24.2%

IWM

+16.1%

Over the past 12 months UTHR returned +25.1% versus DIA (Dow) +10.0%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.2% and IWM (Russell 2000) +16.1%.

Volume & Liquidity 0.67× 3-mo avg

Today 411,674 3-mo avg 616.1K

1.3M

912.0K

616.1K

562.0K

YTD

538.6K

536.1K

UTHR most recently traded 411,674 shares against a 3-month average daily volume of 616.1K.

More News

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

September 30, 2026

From United Therapeutics

Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today

September 30, 2026

United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗

September 24, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗

September 21, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗

September 03, 2026

Via Chartmill

United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗

September 25, 2026

Via MarketBeat

Why United Therapeutics (UTHR) Shares Are Falling Today

September 24, 2026

1 Cash-Heavy Stock to Target This Week and 2 We Question

September 11, 2026

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 08, 2026

United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗

August 20, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗

August 13, 2026

Via Chartmill

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

September 08, 2026

3 Profitable Stocks We’re Skeptical Of

September 03, 2026

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

September 02, 2026

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

September 01, 2026

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

August 28, 2026

3 Cash-Producing Stocks We Keep Off Our Radar

August 26, 2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

August 24, 2026

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

August 17, 2026

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 12, 2026

UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures

August 06, 2026